NCT04795466View on ClinicalTrials.gov

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

March 7, 2024

Study Completion Date

March 7, 2024

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
BIOLOGICAL

Canakinumab

Biological subcutaneous injection

OTHER

Placebo

Matching placebo subcutaneous injection

Trial Locations (10)

101

Novartis Investigative Site, Reykjavik

20520

Novartis Investigative Site, Turku

70210

Novartis Investigative Site, Kuopio

02129

Massachusetts General Hospital, Charlestown

11794-8161

SUNY at Stony Brook, Stony Brook

PL6 8BT

Novartis Investigative Site, Plymouth

GU27YD

Novartis Investigative Site, Guildford

W1G 9JF

Novartis Investigative Site, London

ML1 4UF

Novartis Investigative Site, Motherwell

SO30 3JB

Novartis Investigative Site, Southampton

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY